This is an exciting new approach to plaque reversal.
Quoted:
Plaque Reversal Takes Aim
Repair Biotechnologies received FDA eligibility under the Rare Disease Evidence Principles Pathway for its investigational mRNA therapy, REP-0003, targeting homozygous familial hypercholesterolemia. Rather than simply lowering LDL cholesterol, the therapy aims to remove intracellular cholesterol that drives plaque formation, opening the door to the possibility of reversing cardiovascular damage rather than just slowing it.
Full Episode on YouTube, Spotify and Apple Podcast. Link in the comment.
#repairbiotechnologiesHD #mrnaHD #reverseHD #rep0003HD #fhHD
